Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

ERYTECH makes new appointment to Board of Directors

Authored by Karl Simpson

ERYTECH has announced that Vanessa Mailer will join its Board of Directors in replacement for Dr. Alain Munoz as representative of Idinvest. Vanessa Mailer is a partner with KLS Partners in Paris, a venture capital group focused on early stage investments in the orphan drug and rare diseases field. Prior to her appointment at KLS Partners, Vanessa has a very successful career with Ipsen where she was VP Strategic Planning and Senior Director Business Development Oncology.

ERYTECH is a French biotech company established in Lyon in 2004 which has a lead product in the haematology area. Graspa is being developed in the area of acute lymphoblastic leukaemia (ALL) for relapsing patients. Their most advanced programme is in Phase III and data of the trial is expected to be reported later in the year. A further study is being conducted in the indication of acute myeloid leukaemia (AML). The product is licensed to Orphan Europe (Recordati) in the European markets and with Teva in Israel.

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

Contact Us

   Liftstream Ltd.
67 Grosvenor Street

   Tel: ‚Äč+44 (0)20 3178 5864

Register your CV

Apply for sector specific vacancies or request a confidential discussion

Registered in England No: 5009233
VAT: 843679292

Follow Us